Iqvia Holdings Inc.
IQVIA Announces Planned CFO Transition in Early 2026
Summary
IQVIA Holdings Inc. announced on September 2, 2025, the planned transition of its Chief Financial Officer (CFO) role. Michael J. Fedock will succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer effective February 28, 2026. This transition is part of the company's previously announced CFO succession plan. Mr. Bruehlman will retire and transition to the role of Senior Advisor to the CEO. The appointment and transition were announced via press release under Regulation FD.
Profitelligence Alerts
Get alerts for IQV
Be first to know when Iqvia Holdings Inc. files with the SEC.
Filing Categories
Advertisement
About Iqvia Holdings Inc.
Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.
Official SEC Documents
Advertisement